Nektar Therapeutics (NASDAQ:NKTR) Insider Sells $137,935.89 in Stock

Nektar Therapeutics (NASDAQ:NKTR) insider Jonathan Zalevsky sold 3,867 shares of the business’s stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $35.67, for a total value of $137,935.89. Following the transaction, the insider owned 21,354 shares of the company’s stock, valued at $761,697.18. This represents a 15.33% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Jonathan Zalevsky also recently made the following trade(s):

• On Tuesday, November 25th, Jonathan Zalevsky sold 1,157 shares of Nektar Therapeutics stock. The shares were sold at an average price of $54.28, for a total value of $62,801.96.

Nektar Therapeutics Stock Performance

Shares of NASDAQ:NKTR traded down $0.39 during midday trading on Thursday, hitting $36.53. 600,404 shares of the stock were exchanged, compared to its average volume of 711,764. Nektar Therapeutics has a 52-week low of $6.45 and a 52-week high of $66.92. The business’s fifty day simple moving average is $49.19 and its two-hundred day simple moving average is $44.45. The company has a market capitalization of $743.02 million, a PE ratio of -4.58 and a beta of 1.31.

Nektar Therapeutics (NASDAQ:NKTR) last released its earnings results on Thursday, November 6th. The biopharmaceutical company reported ($1.85) EPS for the quarter, beating the consensus estimate of ($2.85) by $1.00. The firm had revenue of $11.79 million during the quarter, compared to analysts’ expectations of $10.20 million. Nektar Therapeutics had a negative net margin of 192.87% and a negative return on equity of 456.53%. As a group, equities analysts anticipate that Nektar Therapeutics will post -0.72 EPS for the current year.

Hedge Funds Weigh In On Nektar Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of NKTR. Flagship Harbor Advisors LLC purchased a new position in Nektar Therapeutics in the 4th quarter worth approximately $92,000. FNY Investment Advisers LLC increased its position in Nektar Therapeutics by 99.8% during the fourth quarter. FNY Investment Advisers LLC now owns 5,200 shares of the biopharmaceutical company’s stock worth $219,000 after buying an additional 2,598 shares during the period. SG Americas Securities LLC acquired a new stake in Nektar Therapeutics during the 4th quarter worth approximately $463,000. Tudor Investment Corp ET AL purchased a new position in shares of Nektar Therapeutics during the 3rd quarter worth approximately $309,000. Finally, Hudson Bay Capital Management LP purchased a new stake in Nektar Therapeutics during the third quarter worth about $6,127,000. Institutional investors and hedge funds own 75.88% of the company’s stock.

Wall Street Analysts Forecast Growth

NKTR has been the subject of a number of analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Nektar Therapeutics in a research note on Monday, December 29th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Nektar Therapeutics in a report on Wednesday, December 17th. Citigroup initiated coverage on Nektar Therapeutics in a research report on Wednesday, November 26th. They issued a “buy” rating and a $102.00 price target for the company. HC Wainwright lifted their price target on shares of Nektar Therapeutics from $120.00 to $135.00 and gave the stock a “buy” rating in a research note on Tuesday, December 16th. Finally, Wall Street Zen cut shares of Nektar Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, November 16th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $111.83.

About Nektar Therapeutics

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.